Prognostic role of neutrophil to lymphocyte ratio in lung cancers: a meta-analysis including 7,054 patients

Background: Neutrophil to lymphocyte ratio (NLR) has recently been reported to be a poor prognostic indicator in lung cancer. However, the prognostic value of the NLR in patients with lung cancer still remains controversial. We performed a meta-analysis to evaluate the prognostic value of NLR in patients with lung cancer. Methods: We performed a comprehensive literature search in PubMed, Ovid, the Cochrane Library, and Web of Science databases in May 2015. Studies were assessed for quality using the Newcastle–Ottawa Scale. Results: Twenty-two studies with a total of 7,054 patients were included in this meta-analysis. The meta-analysis was performed to generate combined hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS). Our analysis results indicated that high NLR predicted poorer OS (HR, 1.51; 95% confidence interval [CI], 1.33–1.71; P , 0.001) and PFS (HR, 1.33; 95% CI, 1.07–1.67; P = 0.012) in patients with lung cancer. High NLR was also associated with poor OS in lung cancer treated by surgical resection (HR, 1.59; 95% CI, 1.26–1.99; P , 0.001) and chemotherapy (HR, 1.15; 95% CI, 1.08–1.22; P , 0.001). In addition, NLR cut-off value = 5 (HR, 1.57; 95% CI, 1.16–2.12; P = 0.003) and NLR cut-off value , 5 (HR, 1.47; 95% CI, 1.28–1.69; P , 0.001). Conclusion: This meta-analysis result suggested that NLR should have significant predictive ability for estimating OS and PFS in patients with lung cancer and may be as a significant biomarker in the prognosis of lung cancer.

[1]  Jie-wen Peng,et al.  Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment , 2017, Asia-Pacific journal of clinical oncology.

[2]  M. Socinski,et al.  Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Changli Wang,et al.  Prognostic Significance of Combination of Preoperative Platelet Count and Neutrophil-Lymphocyte Ratio (COP-NLR) in Patients with Non-Small Cell Lung Cancer: Based on a Large Cohort Study , 2015, PloS one.

[4]  R. Mehran,et al.  Perioperative neutrophil:lymphocyte ratio and postoperative NSAID use as predictors of survival after lung cancer surgery: a retrospective study , 2015, Cancer medicine.

[5]  P. Iyengar,et al.  Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  X. Qu,et al.  Evaluation of Preoperative Hematologic Markers as Prognostic Factors and Establishment of Novel Risk Stratification in Resected pN0 Non-Small-Cell Lung Cancer , 2014, PloS one.

[7]  A. Gerger,et al.  The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas , 2014, International journal of cancer.

[8]  K. Jeon,et al.  Clinical significance of the neutrophil–lymphocyte ratio in venous thromboembolism patients with lung cancer. , 2014 .

[9]  H. Ling,et al.  The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer , 2014, British Journal of Cancer.

[10]  Zhengwen Liu,et al.  Prognostic role of neutrophil‐to‐lymphocyte ratio in colorectal cancer: A systematic review and meta‐analysis , 2014, International journal of cancer.

[11]  M. Seckl,et al.  Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer , 2014, British Journal of Cancer.

[12]  Wenhui Qian,et al.  Prognostic Role of NLR in Urinary Cancers: A Meta-Analysis , 2014, PloS one.

[13]  T. Kaçan,et al.  Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? , 2014, Asian Pacific journal of cancer prevention : APJCP.

[14]  B. Peng,et al.  Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis , 2014, BMC Cancer.

[15]  Kai Li,et al.  Prognostic Significance of Pretreatment Laboratory Parameters in Combined Small-Cell Lung Cancer , 2014, Cell Biochemistry and Biophysics.

[16]  M. Yıldız,et al.  Prognostic significance of basic laboratory methods in non- small-cell-lung cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[17]  J. Machiels,et al.  Neutrophil:Lymphocyte Ratio and Intraoperative Use of Ketorolac or Diclofenac are Prognostic Factors in Different Cohorts of Patients Undergoing Breast, Lung, and Kidney Cancer Surgery , 2013, Annals of Surgical Oncology.

[18]  M. Yıldız,et al.  Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer. , 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[19]  D. McMillan,et al.  Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer , 2013, British Journal of Cancer.

[20]  A. Rossi,et al.  Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients , 2013, Cancer biology & therapy.

[21]  R. Shi,et al.  Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review , 2013, BMC Cancer.

[22]  Yan-wen Yao,et al.  Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy , 2013, Cancer Immunology, Immunotherapy.

[23]  Seungok Lee,et al.  Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma , 2013, BMC Cancer.

[24]  S. Clarke,et al.  A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer , 2012, British Journal of Cancer.

[25]  E. Felip,et al.  Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer , 2012, Clinical and Translational Oncology.

[26]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[27]  A. Neugut,et al.  Elevated Preoperative Neutrophil:Lymphocyte Ratio as a Predictor of Postoperative Disease Recurrence in Esophageal Cancer , 2011, Annals of Surgical Oncology.

[28]  K. O'Byrne,et al.  The role of inflammation in the pathogenesis of non-small cell lung cancer. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  S. Erdman,et al.  Cancer inflammation and regulatory T cells , 2010, International journal of cancer.

[30]  S. Clarke,et al.  Inflammation and Cancer: Causes and Consequences , 2010, Clinical pharmacology and therapeutics.

[31]  M. Tsuboi,et al.  Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. , 2009, European journal of cancer.

[32]  A. Nicholson,et al.  Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. , 2009, The Journal of thoracic and cardiovascular surgery.

[33]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[34]  Shigemi Matsumoto,et al.  The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric Cancer , 2008, Oncology.

[35]  J. Joyce,et al.  Therapeutic Targeting of the Tumor Microenvironment. , 2021, Cancer discovery.

[36]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[37]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[38]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[39]  J P Vandenbroucke,et al.  Bias in meta-analysis detected by a simple, graphical test , 1998 .

[40]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[41]  M. Dogan,et al.  Assessment of Prognostic Value of "Neutrophil to Lymphocyte Ratio" and "Prognostic Nutritional Index" as a Sytemic Inflammatory Marker in Non-small Cell Lung Cancer. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[42]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[43]  L. Coussens,et al.  The inflammatory tumor microenvironment and its impact on cancer development. , 2006, Contributions to microbiology.

[44]  R. Darveau.  Infection, inflammation, and cancer , 1999, Nature Biotechnology.

[45]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[46]  N. Dubrawsky.  Cancer statistics , 2022 .